Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7627479 | 1.00 | HTR2A (0.41) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL6153867 | 1.00 | HTR2A (0.41) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7498632 | 0.98 | HTR2A (0.40) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6196871 | 0.98 | HTR2A (0.40) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| Mandelic Acid SCHEMBL7684755 | 0.83 | LMNA (0.43) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL24137889 | 0.78 | SIGMAR1 (0.40) | HTR2AHTR2CDRD2SIGMAR1OPRM1 | |
| SCHEMBL6153394 | 0.72 | RBP4 (0.38) | — | |
| SCHEMBL4867850 | 0.72 | RBP4 (0.38) | — | |
| SCHEMBL6153626 | 0.68 | ESR1 (0.36) | KDM1ATSHR | |
| SCHEMBL44425 | 0.67 | HTR2A (0.55) | HTR2AHTR2CDRD2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | NOVO NORDISK A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20070078152-A1 | Piperidine derivatives | AMGEN INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070078152-A1 | Piperidine derivatives | AMGEN INC. | 2007-04-05 | — | — | US | disclosed |
| US-7067535-B2 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20050209262-A1 | Process for producing optically active sulfoxide | SANKYO COMPANY, LIMITED (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1557420-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE | Sankyo Company, Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-0987269-B1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | SANKYO CO (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-1323713-A1 | 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES FOR THEIR SYNTHESIS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6448247-B1 | TACHYKININ RECEPTOR ANTAGONIST; ESPECIALLY TO THE RECEPTORS FOR SUBSTANCE P (WHICH RECEPTORS ARE GENERALLY REFERRED TO AS ?NEUROKININ 1 RECEPTORS?) | SANKYO COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6362179-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | SANKYO COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| EP-0776893-B1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO CO (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-6159967-A | Heterocyclic compounds having tachykinin receptor antagonist activity their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 2000-12-12 | — | — | US | disclosed |
| EP-0987269-A1 | SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE | Sankyo Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0776893-A1 | Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2 | SANKYO COMPANY LIMITED (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105289-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds | HSD11B1, HSD3B1, HSD17B1 | HTR2A 2457/4885HTR2C 2251/4885DRD2 2168/4885 |
| US-20050209262-A1 | Process for producing optically active sulfoxide | TST, TMT1A, PPOX | HTR2A 4624/4885HTR2C 4720/4885DRD2 2053/4885 |
| US-20070078152-A1 | Piperidine derivatives | VIPR2, VIPR1, GRPR | HTR2A 51/4885HTR2C 53/4885DRD2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.